388 related articles for article (PubMed ID: 29379199)
1. Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma.
Zeid R; Lawlor MA; Poon E; Reyes JM; Fulciniti M; Lopez MA; Scott TG; Nabet B; Erb MA; Winter GE; Jacobson Z; Polaski DR; Karlin KL; Hirsch RA; Munshi NP; Westbrook TF; Chesler L; Lin CY; Bradner JE
Nat Genet; 2018 Apr; 50(4):515-523. PubMed ID: 29379199
[TBL] [Abstract][Full Text] [Related]
2. TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma.
Selmi A; de Saint-Jean M; Jallas AC; Garin E; Hogarty MD; Bénard J; Puisieux A; Marabelle A; Valsesia-Wittmann S
Cancer Lett; 2015 Feb; 357(1):412-418. PubMed ID: 25475555
[TBL] [Abstract][Full Text] [Related]
3. Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation.
Murphy DM; Buckley PG; Bryan K; Das S; Alcock L; Foley NH; Prenter S; Bray I; Watters KM; Higgins D; Stallings RL
PLoS One; 2009 Dec; 4(12):e8154. PubMed ID: 19997598
[TBL] [Abstract][Full Text] [Related]
4. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
Aygun N; Altungoz O
Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
[TBL] [Abstract][Full Text] [Related]
5. SMARCE1 promotes neuroblastoma tumorigenesis through assisting MYCN-mediated transcriptional activation.
Hu X; Liu R; Hou J; Peng W; Wan S; Xu M; Li Y; Zhang G; Zhai X; Liang P; Cui H
Oncogene; 2022 Sep; 41(37):4295-4306. PubMed ID: 35978151
[TBL] [Abstract][Full Text] [Related]
6.
Zimmerman MW; Liu Y; He S; Durbin AD; Abraham BJ; Easton J; Shao Y; Xu B; Zhu S; Zhang X; Li Z; Weichert-Leahey N; Young RA; Zhang J; Look AT
Cancer Discov; 2018 Mar; 8(3):320-335. PubMed ID: 29284669
[TBL] [Abstract][Full Text] [Related]
7. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.
Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD
Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979
[TBL] [Abstract][Full Text] [Related]
8. The PLAGL2/MYCN/miR-506-3p interplay regulates neuroblastoma cell fate and associates with neuroblastoma progression.
Zhao Z; Shelton SD; Oviedo A; Baker AL; Bryant CP; Omidvarnia S; Du L
J Exp Clin Cancer Res; 2020 Feb; 39(1):41. PubMed ID: 32087738
[TBL] [Abstract][Full Text] [Related]
9. Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma.
Rajbhandari P; Lopez G; Capdevila C; Salvatori B; Yu J; Rodriguez-Barrueco R; Martinez D; Yarmarkovich M; Weichert-Leahey N; Abraham BJ; Alvarez MJ; Iyer A; Harenza JL; Oldridge D; De Preter K; Koster J; Asgharzadeh S; Seeger RC; Wei JS; Khan J; Vandesompele J; Mestdagh P; Versteeg R; Look AT; Young RA; Iavarone A; Lasorella A; Silva JM; Maris JM; Califano A
Cancer Discov; 2018 May; 8(5):582-599. PubMed ID: 29510988
[TBL] [Abstract][Full Text] [Related]
10. SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma.
Evans L; Chen L; Milazzo G; Gherardi S; Perini G; Willmore E; Newell DR; Tweddle DA
Cancer Lett; 2015 Jul; 363(1):37-45. PubMed ID: 25843293
[TBL] [Abstract][Full Text] [Related]
11. KDM6B promotes activation of the oncogenic CDK4/6-pRB-E2F pathway by maintaining enhancer activity in MYCN-amplified neuroblastoma.
D'Oto A; Fang J; Jin H; Xu B; Singh S; Mullasseril A; Jones V; Abu-Zaid A; von Buttlar X; Cooke B; Hu D; Shohet J; Murphy AJ; Davidoff AM; Yang J
Nat Commun; 2021 Dec; 12(1):7204. PubMed ID: 34893606
[TBL] [Abstract][Full Text] [Related]
12. IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression.
Hagemann S; Misiak D; Bell JL; Fuchs T; Lederer MI; Bley N; Hämmerle M; Ghazy E; Sippl W; Schulte JH; Hüttelmaier S
Mol Cancer; 2023 May; 22(1):88. PubMed ID: 37246217
[TBL] [Abstract][Full Text] [Related]
13. Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data.
Hsu CL; Chang HY; Chang JY; Hsu WM; Huang HC; Juan HF
Oncotarget; 2016 Jun; 7(24):36293-36310. PubMed ID: 27167114
[TBL] [Abstract][Full Text] [Related]
14. Druggable epigenetic suppression of interferon-induced chemokine expression linked to
Seier JA; Reinhardt J; Saraf K; Ng SS; Layer JP; Corvino D; Althoff K; Giordano FA; Schramm A; Fischer M; Hölzel M
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016720
[TBL] [Abstract][Full Text] [Related]
15. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J
Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771
[TBL] [Abstract][Full Text] [Related]
16. Co-localization of the oncogenic transcription factor MYCN and the DNA methyl binding protein MeCP2 at genomic sites in neuroblastoma.
Murphy DM; Buckley PG; Das S; Watters KM; Bryan K; Stallings RL
PLoS One; 2011; 6(6):e21436. PubMed ID: 21731748
[TBL] [Abstract][Full Text] [Related]
17. The KAT module of the SAGA complex maintains the oncogenic gene expression program in
Malone CF; Mabe NW; Forman AB; Alexe G; Engel KL; Chen YC; Soeung M; Salhotra S; Basanthakumar A; Liu B; Dent SYR; Stegmaier K
Sci Adv; 2024 May; 10(22):eadm9449. PubMed ID: 38820154
[TBL] [Abstract][Full Text] [Related]
18. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
[TBL] [Abstract][Full Text] [Related]
19. The super elongation complex drives transcriptional addiction in
Wang D; Yin Z; Wang H; Wang L; Li T; Xiao R; Xie T; Han R; Dong R; Liu H; Liang K; Qing G
Sci Adv; 2023 Mar; 9(13):eadf0005. PubMed ID: 36989355
[No Abstract] [Full Text] [Related]
20. MYCN drives oncogenesis by cooperating with the histone methyltransferase G9a and the WDR5 adaptor to orchestrate global gene transcription.
Liu Z; Zhang X; Xu M; Hong JJ; Ciardiello A; Lei H; Shern JF; Thiele CJ
PLoS Biol; 2024 Mar; 22(3):e3002240. PubMed ID: 38547242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]